<?xml version="1.0"?>
<case>
<name>Alphapharm Pty Ltd v H Lundbeck A/S (No 2) [2008] FCA 1036 (10 July 2008)</name>
<AustLII>http://www.austlii.edu.au/au/cases/cth/FCA/2008/1036.html</AustLII>
<citphrases>
<citphrase id="cp0.0" type=cited from="[2008] FCAFC 107">costs</citphrase>
<citphrase id="cp0.1" type=cited from="[2008] FCAFC 107">appellant successful overall but not on all issues</citphrase>
<citphrase id="cp0.2" type=cited from="[2008] FCAFC 107">discretion to apportion costs on an issue by issue basis</citphrase>
<citphrase id="cp0.3" type=cited from="[2008] FCAFC 107">whether departure from usual rule is appropriate</citphrase>
<citphrase id="cp1.0" type=cited from="[2008] FCA 559">patents</citphrase>
<citphrase id="cp1.1" type=cited from="[2008] FCA 559">validity</citphrase>
<citphrase id="cp1.2" type=cited from="[2008] FCA 559">patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer</citphrase>
<citphrase id="cp1.3" type=cited from="[2008] FCA 559">patentee also held previous patent for the racemate</citphrase>
<citphrase id="cp1.4" type=cited from="[2008] FCA 559">both the racemate and the enantiomer, drugs for the treatment of depression</citphrase>
<citphrase id="cp1.5" type=cited from="[2008] FCA 559">(+)-citalopram claimed to be therapeutically more effective than citalopram</citphrase>
<citphrase id="cp1.6" type=cited from="[2008] FCA 559">challenge to validity of claim for (+)-citalopram</citphrase>
<citphrase id="cp1.7" type=cited from="[2008] FCA 559">construction of claim</citphrase>
<citphrase id="cp1.8" type=cited from="[2008] FCA 559">whether for (+)-enantiomer as an independently existing molecule or whether also for (+)-enantiomer when part of racemate</citphrase>
<citphrase id="cp1.9" type=cited from="[2008] FCA 559">whether claim for (+)-enantiomer anticipated by patent for citalopram</citphrase>
<citphrase id="cp1.10" type=cited from="[2008] FCA 559">whether (+)-enantiomer as an independent molecule was obvious</citphrase>
<citphrase id="cp1.11" type=cited from="[2008] FCA 559">australian test for obviousness</citphrase>
<citphrase id="cp1.12" type=cited from="[2008] FCA 559">application of that test to product claims for the (+)-enantiomer, and to method claim for the method of obtaining it</citphrase>
<citphrase id="cp1.13" type=cited from="[2008] FCA 559">lack of utility</citphrase>
<citphrase id="cp1.14" type=cited from="[2008] FCA 559">product claim for a dosage that, inter alia , was less than and more than a useful dosage range. held : (1) upon its proper construction, product claimed was the independently existing enantiomer; (2) the invention of the independently existing enantiomer was not anticipated by the patent for the racemate; (3) the australian "matter of routine" test for obviousness, when applied to the invention of the product, equated to the question whether those skilled in the art, as a matter of routine, would have had the goal of obtaining separate enantiomers in the expectation that one would be a desirable drug for the treatment of depression; (4) one of the product claims relating to dosage failed test of utility; (5) on the evidence, neither the (+)-enantiomer nor the method for obtaining it was obvious at the priority date.   patents</citphrase>
<citphrase id="cp1.15" type=cited from="[2008] FCA 559">extension of term</citphrase>
<citphrase id="cp1.16" type=cited from="[2008] FCA 559">patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer</citphrase>
<citphrase id="cp1.17" type=cited from="[2008] FCA 559">patentee also held previous patent for the racemate</citphrase>
<citphrase id="cp1.18" type=cited from="[2008] FCA 559">both the racemate and the enantiomer, drugs for the treatment of depression</citphrase>
<citphrase id="cp1.19" type=cited from="[2008] FCA 559">(+)-citalopram claimed to be therapeutically more effective than citalopram</citphrase>
<citphrase id="cp1.20" type=cited from="[2008] FCA 559">both cipramil (goods based on racemic citalopram) and lexapro (goods based on (+)-citalopram) entered in australian register of therapeutic goods (artg)</citphrase>
<citphrase id="cp1.21" type=cited from="[2008] FCA 559">application for extension of term of patent for (+)-citalopram</citphrase>
<citphrase id="cp1.22" type=cited from="[2008] FCA 559">commissioner of patents initially granted extension sought</citphrase>
<citphrase id="cp1.23" type=cited from="[2008] FCA 559">subsequently, following hearing before her delegate, decided to reduce term of extension on ground that "first regulatory approval date" was date when goods cipramil based on racemate had been entered in artg</citphrase>
<citphrase id="cp1.24" type=cited from="[2008] FCA 559">appeal by patentee</citphrase>
<citphrase id="cp1.25" type=cited from="[2008] FCA 559">opponent pharmaceutical company contending that no extension at all should have been granted because application for extension had been made outside six month period following date of first inclusion in artg of goods containing the (+)-enantiomer, namely, cipramil, of which the active pharmaceutical substance was the racemate</citphrase>
<citphrase id="cp1.26" type=cited from="[2008] FCA 559">questions of proper construction of patents act 1990 (cth) ss 70 , 71 , 77</citphrase>
<citphrase id="cp1.27" type=cited from="[2008] FCA 559">whether goods based on racemate "contain" individual enantiomer</citphrase>
<citphrase id="cp1.28" type=cited from="[2008] FCA 559">meaning of "first regulatory approval date" in s 70(5) of act. held : (1) cipramil contained pharmaceutical substance (+)-citalopram; (2) application for extension of term of patent had not been made within six months of first inclusion in artg of cipramil; (3) in circumstances, commissioner had lacked power to grant any extension to term of patent; (4) register of patents to be rectified by removal of particulars of extension.   patents</citphrase>
<citphrase id="cp1.29" type=cited from="[2008] FCA 559">infringement</citphrase>
<citphrase id="cp1.30" type=cited from="[2008] FCA 559">patent for (+)-enantiomer of the racemate, citalopram, and for method of obtaining that enantiomer</citphrase>
<citphrase id="cp1.31" type=cited from="[2008] FCA 559">generic company applying to therapeutic goods administration (tga) for registration of generic drug based on (+)-enantiomer of citalopram</citphrase>
<citphrase id="cp1.32" type=cited from="[2008] FCA 559">whether doctrine of "mechanical equivalents" or "non-essential integers" applicable to method of obtaining pharmaceutical compound</citphrase>
<citphrase id="cp1.33" type=cited from="[2008] FCA 559">generic pharmaceutical company producing generic drug only for purpose of applying for regulatory approval</citphrase>
<citphrase id="cp1.34" type=cited from="[2008] FCA 559">s 78(2) of patents act 1990 (cth).</citphrase>
<citphrase id="cp2.0" type=cited from="[2006] FCAFC 52">trade marks</citphrase>
<citphrase id="cp2.1" type=cited from="[2006] FCAFC 52">application for leave to appeal to full court from judgment of a single judge</citphrase>
<citphrase id="cp2.2" type=cited from="[2006] FCAFC 52">opposition proceeding</citphrase>
<citphrase id="cp2.3" type=cited from="[2006] FCAFC 52">where single judge ordered applications proceed to registration and marks subsequently registered</citphrase>
<citphrase id="cp2.4" type=cited from="[2006] FCAFC 52">where no application for stay of single judge's orders</citphrase>
<citphrase id="cp2.5" type=cited from="[2006] FCAFC 52">whether obligation to register marks after judgment on appeal from registrar's decision under s 68(1)(b)</citphrase>
<citphrase id="cp2.6" type=cited from="[2006] FCAFC 52">whether full court has power to rectify register through cancellation or removal of marks pursuant to trade marks act , federal court of australia act or to preserve subject matter of appeal</citphrase>
<citphrase id="cp2.7" type=cited from="[2006] FCAFC 52">exercise of discretion trade marks</citphrase>
<citphrase id="cp2.8" type=cited from="[2006] FCAFC 52">colour mark</citphrase>
<citphrase id="cp2.9" type=cited from="[2006] FCAFC 52">test under s 41(6)</citphrase>
<citphrase id="cp2.10" type=cited from="[2006] FCAFC 52">whether determine full scope of mark when applying s 41(6)</citphrase>
<citphrase id="cp2.11" type=cited from="[2006] FCAFC 52">test for leave to appeal in an opposition to registration</citphrase>
<citphrase id="cp2.12" type=cited from="[2006] FCAFC 52">failure to consider matters raised</citphrase>
<citphrase id="cp2.13" type=cited from="[2006] FCAFC 52">leave to appeal granted</citphrase>
<citphrase id="cp5.0" type=cited from="[1986] FCA 382">trade practices</citphrase>
<citphrase id="cp5.1" type=cited from="[1986] FCA 382">application under s.82 and accrued jurisdiction</citphrase>
<citphrase id="cp5.2" type=cited from="[1986] FCA 382">judgment in favour of applicant</citphrase>
<citphrase id="cp5.3" type=cited from="[1986] FCA 382">form of judgment</citphrase>
<citphrase id="cp5.4" type=cited from="[1986] FCA 382">whether injunctive relief appropriate  costs</citphrase>
<citphrase id="cp5.5" type=cited from="[1986] FCA 382">applicant unsuccessful in many of the issues raised by him</citphrase>
<citphrase id="cp5.6" type=cited from="[1986] FCA 382">whether entitled to costs of the action</citphrase>
<citphrase id="cp5.7" type=cited from="[1986] FCA 382">award of costs in discretion of court</citphrase>
<citphrase id="cp5.8" type=cited from="[1986] FCA 382">summary of principles upon which discretion exercised</citphrase>
</citphrases>
<citances>
</citances>
<legistitles>
<title id="l0">FEDERAL COURT OF AUSTRALIA ACT 1976 </title>
<title id="l1">FEDERAL COURT OF AUSTRALIA ACT 1976 - SECT 43 Costs</title>
<title id="l2">PATENTS ACT 1990 </title>
<title id="l3">PATENTS ACT 1990 - SECT 19 Certificate of validity</title>
<title id="l4">PATENTS ACT 1990 - SECT 187 Registration of particulars of patents etc.</title>
<title id="l5">PATENTS ACT 1990 - SECT 192 Orders for rectification of Register</title>
<title id="l6">TRADE MARKS ACT 1995 </title>
<title id="l7">TRADE MARKS ACT 1995 - SECT 68 Obligation to register</title>
<title id="l8">FEDERAL COURT RULES </title>
</legistitles>
</case>